Anti Infective Agents Impact in COVID-19 Pneumonia (AZITHROVID)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04453501|
Recruitment Status : Completed
First Posted : July 1, 2020
Last Update Posted : July 1, 2020
During COVID-19 epidemic, hydroxychloroquine was proposed and authorized as a possible key agent in the treatment of COVID-19 hospitalized pneumonia, including in France. Gautret et al. proposed the combination regimen with azithromycin. However only one study reported the interest of azithromycin alone.
Retrospective study reporting the impact of the anti-infective agents used during the pandemic in a tertiary care hospital, using azithromycin with or without hydroxychloroquine.
|Condition or disease||Intervention/treatment|
|COVID Pneumonia, Viral||Drug: favorable outcome|
|Study Type :||Observational|
|Actual Enrollment :||132 participants|
|Official Title:||Interest of Azithromycin With or Without Hydroxychloroquine for the Treatment of COVID-19 Pneumonia : a Retrospective Observational Study|
|Actual Study Start Date :||March 2, 2020|
|Actual Primary Completion Date :||April 25, 2020|
|Actual Study Completion Date :||April 25, 2020|
Azithromycin or non-azithromycin group
Patient who received during admission for a severe COVID-19 pneumonia, azithromycin +/-hydroxychloroquine or no azithromycin.
Drug: favorable outcome
Whether patient under such regimen had a favorable outcome (no transfer in intensive care unit or death)
- Favorable outcome [ Time Frame: Assessed within 7 days after admission ]After being admitted, patient was monitored whether he does not required to be transferred in ICU or died because of a severe COVID-19 pneumonia within 7 days. The outcome was purely clinical. If patient was discharged at home after admission and/or was transferred into a rehabilitation center he was considered as a favorable outcome independently of any biological marker.
- Risk factors 1 [ Time Frame: Assessed at day 1 ]Studying if biological abnormalities (lymphocyte count or CRP) at admission were associated with an unfavorable outcome
- Risk factors 2 [ Time Frame: Assessed at day 1 ]Studying if comorbidities were associated with an unfavorable outcome
- Interest of anti-infective agents [ Time Frame: From date of inclusion until the date of first documented progression to ICU or date of death from any cause, whichever came first, assessed up to 2 months ]Studying whether any regimen was associated with a favorable outcome (including azithromycin)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04453501
|Garches, France, 92380|